We look for and find great opportunities
Blackhawk Growth Corp. is an investment issuer looking to capitalize on market and industry trends that can create substantial value for its shareholders. We look for opportunities all over the globe where we can leverage our knowledge, expertise, and experience to deliver substantial growth for our companies and our investors.
Blackhawk drives its growth by investing in equity and debt instruments of companies and generating positive returns with minimal risk for shareholders. The company’s strategy is focused on investing in multiple companies across a variety of sectors across North America.
Medigen Biotechnology Corp. & TBG Biotechnology Corp.
Blackhawk signed a definitive agreement with Medigen Biotechnology Corporation and TBG Biotechnology Corp. to distribute certain diagnostic products, including an ExProbe SARS-CoV-2 Testing Kit and a SARS-CoV-2 IgG/IgM Rapid Test Kit used in the detection of antibodies associated with COVID-19. Both testing kits are EUA approved by the FDA.
Trip Pharma is currently pursuing the buildout of a purpose-built facility that will provide a supply of high-quality products for use in research and prescription for clinical patients. Trip Pharma intends to conduct research in psilocybin producing mushrooms, is in the process of submitting an application for a Controlled Drugs and Substances Dealers License in Canada and is working to source a library of Psilocybin Cubensis genetics.